Glioblastomas are the most common form of malignant primary brain tumor and an important
cause of morbidity and mortality. In recent years there have been important advances in …

Glioblastoma (GBM) is the most common primary malignant brain tumor, with a universally
poor prognosis. The emergence of molecular biomarkers has had a significant impact on …

Importance Clinical outcomes for glioblastoma remain poor. Treatment with immune
checkpoint blockade has shown benefits in many cancer types. To our knowledge, data from …

Abstract Background Depatuxizumab mafodotin (Depatux-M) is a tumor-specific antibody–
drug conjugate consisting of an antibody (ABT-806) directed against activated epidermal …

The management of patients with glioma usually requires multimodality treatment including
surgery, radiotherapy, and systemic therapy. Accurate neuroimaging plays a central role for …

Background Isocitrate dehydrogenase (IDH) wildtype (wt) grade II gliomas are a rare and
heterogeneous entity. Survival and prognostic factors are poorly defined. Methods We …

Glioblastoma is a poorly immunogenic cancer, and the successes with recent
immunotherapies in extracranial malignancies have, so far, not been translated to this …

The diagnosis of a glioblastoma is mainly made on the basis of their microscopic
appearance with the additional determination of epigenetic as well as mutational analyses …

Background Magnetic resonance imaging (MRI) and amino acid positron-emission
tomography (PET) of the brain contain a vast amount of structural and functional information …

Tumor-educated platelets (TEPs) are potential biomarkers for cancer diagnostics. We
employ TEP-derived RNA panels, determined by swarm intelligence, to detect and monitor …